IRCT2013110415276N1已完成2 期
Evaluating Lamotrigine in relapse prevention following intravenous ketamine in 18-65 years old patients with treatment resistant depression in ziaeian hospital in 2013-2014 in a pilot study
Vice chancellor for research, Tehran University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •1- patients 18 to 65 years 2- be able to understand the intervention 3- submit their written consent. 4- Being infected with treatment-resistant depression diagnosed by a psychiatrist. 5- current depressive episode lasting 4 to 6 weeks. 6- Be at least at the second stage of TRD (Failure to respond to antidepressant treatment with 2 drug families in the current episode based on Antidepressant Treatment History Form). 7- HDRS score of 21 with Hamilton scoring is higher or equal to 18. 8- Women of reproductive age have negative ßHCG and use reliable method of contraception during the study period.
- •Exclusion criteria: 1- patients with depression secondary to medical illness, drug or alcohol abuser (except nicotine and caffeine) according to the criteria of DSMIV.
- •2- pregnant or lactating women. 3- patients with a history of seizure disorder other than epilepsy and fever. 4- patients with a known history of intolerance or sensitivity to ketamine and lamotrigine. 5- patients with diagnosis of schizophrenia and bipolar disorder, and psychotic signs. 6- patients with Tourette syndrome, autism and mental retardation. 7- patients at serious risk of suicide and homicide. 8- patients with obstructive sleep apnea or a history of difficult airway management in previous anesthesia. 9- patients treated with MAO irreversible inhibitors during the two weeks prior to the intervention. 10- patients with clinical and laboratory evidence of medical disorders, such as impaired hepatic or renal function, coronary disease, cerebrovascular disease, viral hepatitis B and C, acquired immunodeficiency syndrome, diabetes mellitus, uncontrolled hypertension, unmodified hypothyroidism or hyperthyroidism, neurological , immunological or hematologic disorders and in general, patients with clearly abnormal findings in laboratory tests, physical examination, or electrocardiogram.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Epilepsy management in elderlyElderly epilepsy.EpilepsyIRCT2013021211560N3Deputy of Research,Tehran University of Medical Sciences95
已完成
不适用
Observational Study of LamotrigineEpilepsyNCT00299793Northwell Health60
已完成
4 期
Study of Efficacy of Lamotrigine in Therapy of Bronchial AsthmaBronchial AsthmaNCT00153244Centre of Chinese Medicine, Georgia76
已完成
4 期
Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine DependencyCocaine DependenceBipolar DisorderNCT00280293University of Texas Southwestern Medical Center112
已完成
4 期
Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated PatientsMemory Impairment Due to Corticosteroid UseHypomania Due to Corticosteroid UseHippocampal Atrophy Due to CorticosteroidNCT00223262University of Texas Southwestern Medical Center28